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Bradykinin  exerts  its vascular  actions  via  two  types  of receptors,  the  non-constitutively  expressed
bradykinin  receptor  type  1  (BR1)  and the  constitutive  type  2 receptor  (BR2).  Bradykinin-induced  vasore-
laxation  is  age-dependent,  a phenomenon  related  to the  varying  amounts  of  BR1  and BR2  in the
vasculature.
Isoleucine-proline-proline  (Ile-Pro-Pro),  a  bioactive  tripeptide,  lowers  elevated  blood  pressure  and
improves  impaired  endothelium-dependent  vasorelaxation  in  hypertensive  rats.  It inhibits  angiotensin
converting  enzyme  1 (ACE1).  Other  mechanisms  of action  have  also  been  postulated.
The  aims  of the  study  were  to  clarify  the  underlying  mechanisms  of the  age-dependency  of  bradykinin-
induced  vasodilatation  such  as the  roles  of  the  two  bradykinin  receptors,  the mas-receptor  and  synergism
with  Ile-Pro-Pro.
The vascular  response  studies  were  conducted  using  mesenteric  artery  and  aorta  rings from  nor-
motensive  6  wk.  (young)  and  22  wk.  (old)  Wistar  rats.  Cumulative  dosing  of acetylcholine,  bradykinin
and  angiotensin(1–7)  (Ang(1–7))were  tested  in  phenylephrine-induced  vasoconstriction  with or  without
10  min  pre-incubation  with  antagonists  against  BR1-,  BR2-  or mas-receptors,  Ang(1–7)  or ACE1-inhibitors
captopril  and Ile-Pro-Pro.
The  bradykinin-induced  vasorelaxation  in  vitro  was  age-dependent  and  it was  improved  by pre-
incubation  with  Ile-Pro-Pro,  especially  in old  rats  with  endothelial  dysfunction.  The  mas-receptor
antagonist,  D-Pro7-Ang(1–7)  abolished  bradykinin-induced  relaxation  totally.  Interestingly,  BR1  and  BR2
antagonists  only  slightly  reduced  bradykinin-induced  vasorelaxation,  as an  evidence  for the  involvement
of  other  mechanisms  in  addition  to receptor  activation.
In  conclusion,  bradykinin-induced  vasorelaxation  was  age-dependent  and  Ile-Pro-Pro  improved  it.
Mas receptor  antagonist  abolished  relaxation  while  bradykinin  receptor  antagonist  only  slightly  reduced
it, suggesting  that bradykinin-induced  vasorelaxation  is  regulated  also  by other  mechanisms  than  the
classical  BR1/BR2  pathway.
© 2016  Elsevier  Inc.  All  rights  reserved.. Introduction
Rocha e Silva and co-workers [38] as early as 1949 were the pio-
eers of bradykinin research. They described that trypsin and some
nake venoms were able to break down plasma globulin to pro-
uce a blood pressure lowering substance which slowly contracted
solated gut preparations in vitro [12,37]. They named the sub-
tance bradykinin (bradys = slow). In the early 1970s, the important
asoregulatory enzyme, angiotensin-converting-enzyme (ACE)
as discovered, and soon afterwards, pharmacological inhibitors
∗ Corresponding author. Faculty of Medicine, Pharmacology, P.O. Box 63, FI 00014
niversity of Helsinki, Finland.
E-mail address: aino.siltari@helsinki.ﬁ (A. Siltari).
ttp://dx.doi.org/10.1016/j.peptides.2016.09.001
196-9781/© 2016 Elsevier Inc. All rights reserved.were developed for the treatment of hypertension. ACE acts on a
circulating inactive decapeptide, angiotensin I, to release the very
potent vasoconstricting octapeptide, angiotensin II. This enzyme
also breaks down the vasodilator nonapeptide, bradykinin into
inactive fragments. In fact, ACE and kininase II are the same enzyme
[8,52]. Thus ACE-inhibitors have dual mechanisms in lowering
blood pressure.
Bradykinin mediates its actions via two  different receptor types;
bradykinin receptor type 1 (BR1) and type 2 (BR2) [37]. BR2 is con-
stitutively expressed in many tissues e.g. vascular endothelium and
smooth muscle cells. BR1 is non-constitutive, but it can be induced
by inﬂammation. BR2 mediates most of the vascular functions of
bradykinin but BR1 can modulate cardiovascular functions when
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nﬂammation is present in the endothelium like in hypertension
29].
Bradykinin-induced vasorelaxation is known to be age-
ependent [28,43]. In young Wistar (6 wk.), Wistar-Kyoto (WKY)
nd spontaneously hypertensive rats (SHR) (both 8 wk) in vitro
vidence of bradykinin-induced vasorelaxation was  seen in mesen-
eric arteries. In 12 week old rats, vasorelaxation was impaired and
y the time, when the rats had aged to 18 and 22 months, the
esponse was totally abolished. In these aged animals, bradykinin
ven constricted the arteries, possibly due to increased produc-
ion of vasoconstricting prostanoids or decreased expression of
he vasodilatory BR2 receptors [21,32]. This age-dependent phe-
omenon was even more pronounced in SHR [9,28].
Several small bioactive peptides are produced from casein
hen milk is subjected to fermentation such as isoleucine-proline-
roline (Ile-Pro-Pro), leucine-proline-proline (Leu-Pro-Pro) and
aline-proline-proline (Val-Pro-Pro) [19]. They all are ACE-
nhibitors and demonstrated to reduce elevated blood pressure
n rats [16,18,45] and in humans (see, meta-analyses [3,36,46,50].
urthermore, they partially restored impaired endothelium-
ependent vascular relaxation in hypertensive rats [16,18,45].
lthough the main mechanism of action of these peptides are pos-
ulated to be angiotensin converting enzyme 1 (ACE1) inhibition
25,31,44], this property does not explain all their vasoprotective
ctions.
Present study was aimed to clarify the mechanisms underlying
he age-dependency of bradykinin-induced vasorelaxation, espe-
ially the role of bradykinin- and mas-receptors as well as the
ffects of Ile-Pro-Pro on bradykinin responses, in an in vitro exper-
mental protocol.
. Material and methods
.1. Animals
Normotensive Wistar rats aged 6 wk. (young) and 22 wk.  (old)
ith free access to tap water and rodent basic feed (Harlan, Ross-
orf, Germany) were used. The protocol was approved by the
ational Animal Experimentation Committee of Finland according
o EC Directive 86/609/ECC and the Finnish Experimental Animal
ct 62/2006s.
.2. Vascular response studies
After CO2 anaesthesia, the animals were decapitated, the mesen-
eric arteries and the thoracic part of the descending aorta were
laced in pre-oxygenated (O2/CO2 95%/5%, Aga, Riihimäki, Finland)
ce-cold Krebs buffer (pH 7.4–7.6, composition in mM:  NaCl 119.0,
aHCO3 25.0, glucose 11.1, KCl 4.7, CaCl2 1.6, KH2PO4 1.2, MgSO4
.2). Some sections of the aorta were collected in Allprotect Tissue
eagent (Qiagen, Hilden, Germany) and stored at −20 ◦C for fur-
her analysis of the receptor protein levels of BR2 and the Ang(1–7)
eptide concentration. Changes in vascular tone and endothe-
ial function were measured in standard organ bath chambers
ith a computerized system (EMKA Technologies, Paris, France).
ndothelium-intact superior mesenteric artery and descending
orta rings (about 3 mm long, diameter of aorta appr. 1.2 mm and
esenteric artery appr. 0.8 mm)  without adherent adipose and
onnective tissue were connected to stainless steel hooks (diameter
.1 mm for mesenteric arteries and 0.2 mm for aortas) and placed in
xygenated (O2/CO2 95%/5%) Krebs buffer in organ bath chambers
10 ml,  37 ◦C).
The protocol of test series for vascular function measurements
as as follows: After one hour of equilibration with 1.5 g baseline
one (passive tension caused by stretching) (resting tension was 85 (2016) 46–55 47
selected based on earlier studies: [20,27,30]), vessel rings were con-
tracted using 60 mM potassium chloride (KCl) solutions to initiate
vascular activity, and subsequently this solution was  washed out
before the actual experiments. The presence of functional endothe-
lium was tested by using cumulative (1 nM–10 M)  acetylcholine
(ACh, Sigma-Aldrich, Munich, Germany) doses after phenyle-
phrine (PE, 1 M,  Sigma-Aldrich) contraction. Bradykinin-induced
vascular responses were tested by addition of 1 nM–10 M cumu-
lative bradykinin acetate salt (Bachem, Weil am Rhein, Germany).
Bradykinin type 1 and 2 receptor antagonists (for BR1: 1 M des-
Arg9-Leu8-Bradykinin, (Bachem) for BR2: 0.1 M Hoe-140, (Tocris,
Bristol, UK) and mas-receptor antagonists (A-779, 1 M and D-
Pro7-Ang(1–7), 1 M,  both from Bachem) were used to study the
role of the respective receptors in the bradykinin-induced vasore-
laxation. The concentrations were based on observations from our
earlier studies [5]. However, we are aware that using only one
concentration from each inhibitor, agonist and antagonist is a limi-
tation of the study. This kind of cumulative dosing of acetylcholine
and bradykinin has widely been used in vascular relaxation stud-
ies in vitro. Because bradykinin-induced relaxation responses were
less than 50% of the maximum, EC50- values could not be calculated.
Preincubation for 10 min  with milk casein-derived ACE-
inhibitor Ile-Pro-Pro (1 mM,  Bachem) or the pharmacological
standard ACE-inhibitor, captopril (10 M,  Sigma-Aldrich) was  con-
ducted before contraction and the cumulative bradykinin dosing.
The role of nitric oxide (NO) and prostanoids in vasorelaxation
was evaluated with a 10 min  pre-incubation with the non-speciﬁc
nitric oxide synthase (NOS) inhibitor L-NG-nitroarginine methyl
ester (L-NAME, 100 M,  Sigma-Aldrich) or with the non-speciﬁc
cyclooxygenase (COX) inhibitor diclofenac (3 M,  Sigma-Aldrich)
before contraction with PE and subsequent cumulative bradykinin
dosing. All concentrations were the ﬁnal concentrations in the
cuvette. After every individual test series, the cuvettes were washed
three times with Krebs buffer and the vessels were equilibrated for
20–30 min  before the next measurements. PE-induced constriction
did not alter throughout the measurements of each ring. If ACh-
induced endothelium-dependent vasodilatation was  too small, the
rings were discarded due to distraction of endothelium.
2.3. BR2 receptor protein and Ang(1–7) levels
BR2 receptor protein and Ang(1–7) peptide levels were mea-
sured from rat aorta tissue using commercial ELISA kits (BR2:
Enzyme-linked immunosorbent assay kit for bradykinin receptor
BR2, Rattus norvegicus, Cloud-clone Corp. Houston, Texas, USA,
Ang(1–7) enzyme-linked immunosorbent assay kit for angiotensin
1–7, Rattus norvegicus,  Cloud-clone Corp). According to the com-
pany Cloud-clone Corp the speciﬁcity of antibody against the B2
receptor is reliable and targeted to sequence between amino acids
Gln37-Gln320 of the B2 receptors.
The isolation protocol was  as follows: A small piece of aorta
was cut into small sections using a razor blade and the tissue
was homogenized with small beads (procedure: 5500 rotation
per minute (rpm), 3 times 20 s + 6500 rpm, twice 15 s, Pre-
cellys 24, Bertin Technologies, Montigny le Bretonneux, France)
in Elisa buffer (NaCl 136 mM,  Na2HPO4 8 mM,  KCl 2.7 mM,
KH2PO4 1.46 mM,  Tween 20 0.001%) containing a complete pro-
tease inhibitor cocktail tablet (Roche, Mannheim, Germany). After
homogenization, the samples were stored at 4 ◦C for 30 min  to
decrease foaming and centrifuged at 12000g, 4 ◦C for 15 min. The
total protein concentration of the supernatant was measured using
a Pierce BCA protein assay kit (Thermo Scientiﬁc, IL, USA). All
samples were diluted using Elisa buffer to the same total pro-
tein concentration (0.13 g/l)  before the BR2 and Ang(1–7) assays
were performed.
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.4. RT-qPCR analyses
mRNA isolation protocol was as follow: small piece of frozen
orta was pulverized in liquid nitrogen with mortar and pes-
el. RNA was isolated using Trizol reagent (InVitrogen, Thermo
isher Scientiﬁc, MA,  USA) according manufacturer’s instructions.
rieﬂy, pulverized tissue was homogenized in Trizol reagent using
rezellys homogenator (5500 rpm, 3 × 20 s) following centrifuga-
ion (12 000g, 15 min, 4 ◦C) with chloroform (Sigma-Aldrich). Bright
ayer after centrifugation was stored and washed using isopropanol
Thermo Fisher Scientiﬁc) and ethanol. In the end of the protocol,
ormed pellet of mRNA was diluted into nucleic acid free water
nd total RNA concentration was measured using NanoDrop spec-
rophotometer (Thermo Fisher Scientiﬁc).
One g of mRNA was  converted into complementary DNA
cDNA) using commercial kit (iScript, BioRad, California, USA).
DNA was diluted into 1:5 for ﬁnal RT-qPCR analyses.
In the ﬁnal reaction for qPCR diluted samples (2 l),
asterMix (10 l, iTaq Universal SYBRGreen Supermix, Bio-
ad), forward (F) and reverse primers (R) (1 l each) and
ucleic acid free water (6 l) were added in ﬁnal volume
f 20 l. Primers for ACE1 were F 5′ AGTGGGTGCTGCTCTTC-
TA’3 and R 5′ATGGGACACTCCTCTGTTGG‘3, for BR1 were F
′ AGGGTTCGTCATCACTAT’3 and R 5′AGGTAGATTTCCGCTATG’3,
or BR2 were F 5′TGAGGAACAACGAGATGAAGAAG’3 and R
′GGAAACCAACACAGCACAAAGAC’3 (adapted from [40]) and
or mas-receptors were F 5′TGTGGGTGGCTTTCGATTT’3 and R
′ATTAGACCCCCATGCATGTAGAA’3 (adapted from [51]). Three dif-
erent control genes were used (-actin, GAPDH and LDHA)
nd primers for those were -actin F 5′ AGATCAAGAT-
ATTGCTCCTCCT’3 and R 5′ AAAACGCAGCTCAGTAACAGT’3, GAPDH
 5′GCTGCCTTCTCTTGTGACAA’3 and R 5′ ATCTCGCTCCTGGAA-
ATGG’3 and LDHA F 5′CATCGTGCACTAAGCGGTCC’3 and R 5′
CAAGCTCATCAGCCAAGTC’3. Before the ﬁnal analyses, efﬁciency
f the primer pairs was tested and calculated using dilution series
rom pooled samples. All primers were ordered from Sigma-
ldrich.
RT-qPCR analyses were done using LightCycler 480 Instrument
I (Roche, Espoo, Finland) with protocol of initial in 10 min  95 ◦C
ollowed 40 cycles of denaturation (15 s 95 ◦C), annealing (30 s 60 ◦C
xcept 58 ◦C for mas-receptor) and elongation (30 s 72 ◦C). In the
nd of the protocol melt curve analysis was performed (5 s 95 ◦C,
 min  60 ◦C followed temperature increasing 0.11 ◦C/s until 95 ◦C).
esults were calculated using the method by Vandesompele et al.
48].
.5. Statistical analyses
Statistical analyses were done using GraphPad Prism (version
). Student t-test (two tailed) or one-way analysis of variance
ANOVA,) followed by Tukey’s multiple comparison test was used to
alculate statistical differences. Statistics from the concentration-
esponse curves have been done using all concentrations, if not
entioned otherwise. P-values less than 0.05 were considered
tatistically signiﬁcant. All results are presented as means ± SEM,
xcept RT-qPCR results as geometrical mean and expression of
ndividual samples.
. Results
.1. Vascular responsesAorta rings were considered to represent large arteries (basic
aintenance vessel) whereas mesenteric artery rings were repre-
entatives of smaller resistance arteries, which are more important 85 (2016) 46–55
for blood pressure regulation. The relaxations evoked by cumu-
lative doses of bradykinin and angiotensin(1–7) were tested in
both vascular rings in the presence of different agonists, antag-
onists or inhibitors. Cumulative acetylcholine (ACh) −induced
vasorelaxation was used as a standard endothelium −dependent
measurement to conﬁrm the functionality of the endothelium.
3.1.1. The role of age and tripeptide Ile-Pro-Pro
The ACh −induced, endothelium-dependent vascular relaxation
was impaired in the mesenteric arteries of old rats (Fig. 1A), with
maximal achievable relaxation being only approximately 40% vs.
the almost complete (90%) relaxation obtained in young rats. This
difference was  not seen in the aortas; in that tissue, the maxi-
mum relaxation was  less than 50% in both young and older groups
(Fig. 1B). Phenylephrine-induced vasoconstriction was similar in
the mesenteric arteries and aortas of the young and older rats
(Fig. 1D), although the mesenteric arteries of the young rats were
more sensitive to potassium chloride (KCl) −induced vasoconstric-
tion (p < 0.01) (Fig. 1C).
There was  more evident vasorelaxation evoked by bradykinin
both in mesenteric arteries and aortas of younger rats compared to
that detected in the older rats (mesenteric artery p < 0.01, aorta
p < 0.01) (Fig. 2A). In fact, in the mesenteric arteries of old rats,
bradykinin did not cause any relaxation but produced even a slight
vasoconstriction; a phenomenon which was  more marked in the
aortas (Fig. 2B). Bradykinin neither relaxed nor constricted the aor-
tas of young rats, (Fig. 2B).
Pre-incubation with Ile-Pro-Pro (1 mM)  or Ang(1–7) (10 M) for
10 min  before PE constriction improved bradykinin–induced relax-
ation slightly in the aortas of young rats (p < 0.05.). (Fig. 3B) This
was not seen in mesenteric arteries (Fig. 3A). Unexpectedly, pre-
incubation with the classical ACE-inhibitor, captopril decreased
relaxation in mesenteric arteries (p < 0.05) (Fig. 3A) but had no
effect on aortas (Fig. 3B).
In the mesenteric arteries and aortas of older rats, pre-
incubation with both ACE-inhibitors (Ile-Pro-Pro and captopril)
augmented bradykinin–induced relaxation (mesenteric artery
p < 0.01, aorta p < 0.001) (Fig. 3C and D). Interestingly, Ile-Pro-Pro
slightly improved bradykinin relaxation more than captopril at the
concentrations used especially in aorta (p < 0.05).
3.1.2. The role of bradykinin receptors and mas-receptor
Pre-incubation with the bradykinin receptor blockers i.e.
BR1 antagonist des-Arg9-Leu8-bradykinin and bradykinin BR2-
receptor antagonist Hoe-140, only slightly prevented bradykinin
−induced relaxation in the mesenteric artery rings of young rats
(p = ns., max. relaxation in control 38%, B1 antagonist 21% and B2
antagonist 22%) (Fig. 4A). These compounds had no clear effect on
aorta preparations (Fig. 4B).
The mas-receptor antagonist A-779 increased the ability of
bradykinin to cause relaxation in aorta (p < 0.05) (Fig. 4B) but had
no effect on mesenteric arteries (Fig. 4A). However, another mas-
receptor antagonist D-Pro7-Ang(1–7) abolished relaxation totally
in both vessels (mesenteric artery p < 0.05, aorta p = ns.) (Fig. 4A
and 4B). All antagonists were pre-incubated in the cuvettes for
10 min  before phenylephrine constriction and bradykinin-induced
relaxation.
3.1.3. The role of NOS and COX enzymes
NOS inhibitor L-NAME abolished the bradykinin-induced relax-ation in both vessel preparations (mesenteric artery p < 0.05,
aorta p = ns.). However, a non-selective COX inhibitor diclofenac
decreased relaxation in mesenteric arteries (p < 0.05) and slightly
improved relaxation in aortas. (Fig. 5A and B)
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Fig. 1. Acetylcholine (ACh) −induced vasorelaxation (A, B) and phenylephrine (PE) (C) and 60 mM potassium chloride (KCl) (D) −induced vasoconstriction in mesenteric
arteries  and aortas of young (6 wk.) and old (22 wk.) rats. Data is presented as Mean ± SEM. Mesenteric artery: young n = 16-19 and old n = 7-8. Aorta: young n = 12-15 and
old  n = 6.
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Fig. 2. Bradykinin −induced vasorelaxation in mesenteric arteries (A) and aortas (B) of young (6 wk.) and old (22 wk.) rats. Data is presented as Mean ± SEM. Mesenteric
artery:  young n = 32 and old n = 8. Aorta: young n = 28 and old n = 6.
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Fig. 3. Effects of 10 min  pre-incubation with Ile-Pro-Pro, Ang(1–7) or captopril on bradykinin −induced relaxation of vessels of young (6 wk.) and old (22 wk.) rats. Data
is  presented as Mean ± SEM. Young mesenteric artery (A): control n = 6, Ile-Pro-Pro n = 8, Ang(1–7) n = 14, Captopril n = 4. Young aorta (B): Control n = 6, Ile-Pro-Pro n = 6,
Ang(1–7) n = 12, Captopril n = 6. Old mesenteric artery (C): Control n = 10, Ile-Pro-Pro n = 6321, Captopril n = 4. Old aorta (D): Control n = 6, Ile-Pro-Pro n = 6, Captopril n = 4.
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-779  n = 10, D-Pro7-Ang(1–7) n = 6. Aorta (B): Control n = 15, BR1 antagonist n = 3, .1.4. Ang(1–7)-induced vasorelaxation
Although cumulative doses of Ang(1–7) produced vasorelax-
tion in both vessels, the extent of the relaxation was more
arked in the mesenteric artery (Fig. 6A and 6B). A ten minuteM), BR2 antagonists Hoe-140 (0.1 M)  and mas-receptor antagonist A-779 (1 M)
M. Mesenteric artery (A): Control n = 14, BR1 antagonist n = 4, BR2 antagonist n = 8,
tagonist n = 6, A-779 n = 6, D-Pro7-Ang(1–7) n = 7.pre-incubation with captopril slightly improved the relaxation in
aorta (p < 0.05) (Fig. 6B). Ile-Pro-Pro slightly improved relaxation
in mesenteric arteries in smaller Ang(1–7) concentrations and
decreased relaxation on the level of control in higher Ang(1–7)
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Fig. 6. Angiotensin(1–7) (Ang(1–7)) −induced vasorelaxation in the vessels of young (6 wk.) rats. Preincubation of 10 min  with Ile-Pro-Pro, captopril or mas-receptor
antagonist A-779 or D-Pro7-Ang(1–7) before constriction and cumulative Ang(1–7) dosing. Data is presented as Mean ± SEM. Mesenteric artery (A): Control n = 13, Ile-Pro-
Pro  n = 5, Captopril n = 8. Aorta (B): Control n = 13, Ile-Pro-Pro n = 6, Captopril n = 7. Mesenteric artery (C): Control n = 12, A-779 n = 10, D-Pro7-Ang(1–7)n = 5. Aorta (D): Control
n  = 14, A-779 n = 8, D-Pro7-Ang(1–7) n = 7.
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Fig. 7. Relative mRNA expression of BR1 and BR2 receptors, ACE1 and mas-receptors i
expression of individual sample (symbol). N = 5-6 in each group.
Table 1
Levels of bradykinin receptor type 2 protein and angiotensin(1–7) peptide from
young (6 wk.) and old (22 wk.) rats aorta. Mean ± SEM values were calculated as a
proportion of the total protein values of the samples (pg/g of total protein). Data
is  presented as Mean ± SEM. N = 5-6 in each group.
Young Old
Bradykinin receptor type 2 130.4 ± 7.9 130.4 ± 11.9
Angiotensin(1–7) 0.156 ± 0.013 0.127 ± 0.013
c
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m
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r
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a
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t
teric artery and aorta rings of young (6 wk.) and old (22 wk.)
normotensive rats. We  tested several pharmacological antagonistsoncentrations (Fig. 6A). It had no effect on aortas (Fig. 6B).
nexpectedly, a pre-incubation with A-779, an antagonist of the
as-receptor (i.e. the receptor for Ang(1–7)), only slightly inhibited
ng(1–7) −induced relaxation in mesenteric arteries (p = ns., max.
elaxation in control 31% and A-779 23%) and had no effect on aorta
Fig. 6C and D). However, D-Pro7-Ang(1–7), another mas-receptor
ntagonist, abolished the relaxation in both vessels (mesenteric
rtery p < 0.01, aorta p = ns.).
.2. Protein levels
There were no differences in bradykinin receptor BR2 protein
nd Ang(1–7) peptide levels between young and old rats’ aorta
Table 1). Measured values were calculated as a proportion of the
otal protein values of the samples.n young and old rat aorta. Results are presented as geometrical mean (line) and
3.3. Gene expression levels
There were no statistical differences in bradykinin receptor BR1
and BR2, ACE1 or mas-receptor mRNA expression levels between
young and old rats’ aorta (Fig. 7). However, ACE1 gene expression
showed to be slightly higher in old rats compared to younger ones
(p = 0.0615).
4. Discussion
The age-dependency of bradykinin −induced vasodilatation has
been postulated to be due to the fact that ageing changes the
expression pattern of the bradykinin receptors [21,32]. The den-
sity of BR2 is reduced whereas that of BR1 seems to be elevated by
ageing that changes the balance towards vasoconstrictory recep-
tors. It has also been suggested that the vasodilator as well as other
cardioprotective actions of bradykinin in arteries result from the
activation of the BR2 subtype [23,28]. Thus, because the number of
BR2 receptors decline during ageing, these actions of bradykinin are
abolished and possibly even converted into vasoconstrictive effects,
which could evoke ischemic damage in the heart [28]. In general,
it seems that with ageing, the levels of kinins actually increase but
their response in the target cells reduces [35].
The present study examined the effects of bradykinin on mesen-to determine the possible contributions of the two  bradykinin
receptors as well as the mas-receptor. Bradykinin induced a
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asorelaxation which was age-dependent in both the mesen-
eric artery and aorta. A weak ACE1-inhibitory peptide, Ile-Ile-Pro,
ugmented the effects of bradykinin in the same manner as
he mas-receptor agonist, Ang(1–7). Interestingly, BR1- and BR2-
ntagonists only slightly reduced the vasodilatory effects of
radykinin, suggesting that other mechanisms may  be involved in
his phenomenon in addition to BR receptor activation.
Another part of the classical renin-angiotensin-system (RAS),
.e. the heptapeptide angiotensin (Ang(1–7)) −mas-receptor axis
see [2,41]) which may  also play a role in bradykininı´s vasoprotec-
ive actions. Ang(1–7), a break-down product by ACE2, has been
emonstrated to potentiate bradykinin-induced vasorelaxation
10,11,33,34,47]. We  have previously shown that also a bioactive
ripeptide, Ile-Pro-Pro, has synergistic effects on bradykinin-
nduced vasodilatation in mesenteric artery preparations obtained
rom SHR [5].
Here we describe that ACh −induced endothelium-dependent
elaxation after phenylephrine (PE) constriction was impaired in
he mesenteric arteries of older rats, (Fig. 1) probably due to some
egree of endothelial dysfunction in the aged smaller arteries. This
ge-dependent impairment was not seen in the aortas, suggesting
hat if dysfunction develops at all in these vessels, it only appears
ater than in the small arteries. However, after PE constriction, the
aximal ACh −induced relaxation was only 50% from the baseline
n both young and old rats, indicating that the aorta is not the most
uitable blood vessel for studies on endothelium function.
It has been proposed that ageing also decreases the extent of
asoconstriction via an endothelium-dependent mechanism. Ship-
ey and Muller-Delp [42] described that the responsiveness of coro-
ary resistance arterioles to potassium chloride in both young and
ld rats and concluded that the decreased constriction observed in
he coronary arteries of old rats was endothelium-dependent. In
ur study, although the level of non-receptor mediated vasocon-
triction to potassium chloride was decreased in the mesenteric
rteries of old rats (Fig. 1), there was no evidence of impaired
onstriction to phenylephrine (receptor mediated). This ﬁnding
upports the concept that these old rats exhibited some degree
f endothelial dysfunction in their mesenteric arteries which may
ave been reﬂected also in their smooth muscle function.
Bradykinin induced relaxation in the mesenteric arteries of
ormotensive young rats, but caused slight vasoconstriction in
he aortas of older rats (Fig. 2). Previously, Mantelli et al [28]
nvestigated the effects of bradykinin in mesenteric arteries from
pontaneously hypertensive rats. The vasoconstriction in old rats
as equal or even stronger than that in normotensive rats. It is
elieved that vasodilatation is regulated via BR2 and BR1 recep-
ors whereas vasoconstriction is attributable to the release of
rostanoids [21,28,32,49]. Endothelial inﬂammation seen in hyper-
ension [15] and during ageing [6] can inﬂuence on various
ndogenous agents. The rats in our study were normotensive, thus
ven the old animals may  have minor local inﬂammation in the
ndothelial lining their blood vessels (see, [6,15]).
BR1 has been shown to have a more evident role in disease states
here there is the presence of inﬂammation [29]. It may  be that
R2 receptors are more important in bradykinin-induced actions
uring ageing in healthy rats. Interestingly, there was  no differ-
nce in mRNA expression (Fig. 7) or the protein levels (Table 1)
f BR2 receptors between the young and old groups, although
radykinin-induced vasorelaxation was impaired in the vessels of
ld rats. This phenomenon differs from the previous ﬁndings by our
roup [32] and others [21,49]. We  found no statistical difference in
RNA expression of mas-receptors and BR1 receptors between theroups. It seems that mas-receptor protein expression decreased
uring ageing in rats suffering metabolic syndrome [14,39] and
ardiac hyperthrophy and myocardial infarctions [4]. Rats in the
resent study were healthy. 85 (2016) 46–55 53
The pre-incubation with two  ACE-inhibitors, the tripep-
tide Ile-Pro-Pro and the standard agent, captopril augmented
bradykinin-induced relaxation especially in the vessels of old rats
(Fig. 3). Both compounds act as ACE1 inhibitors and thus prevent
the degradation of bradykinin into its inactive fragments. However,
it seems that Ile-Pro-Pro may  possess also other mechanisms of
action, especially in the vessels of old rats, because Ile-Pro-Pro was
able to improve bradykinin-induced relaxation more than capto-
pril, at the concentrations used.
Interestingly, captopril had no effect on vessels of the young rats,
but it increased bradykinin-induced vasodilatation in vessels of old
rats (Fig. 3). It has been shown that ACE1 activity increases during
ageing in aorta [7,22]. It is possible that activity of the ACE1 does
not affect the degradation of bradykinin in vessels of young ani-
mals, thus inhibition of ACE1 does not improve bradykinin-induced
vasodilatation. In arteries of old rats, ACE1 activity is increased and
bradykinin is degraded by this enzyme. Based on that, inhibition of
ACE1 by captopril improves bradykinin-induced vasodilatation.
Previous studies by our group and others [5,33,47], have
revealed that Ang(1–7) is able to augment bradykinin-induced
vasodilatation. However, in the present study Ang(1–7) only
slightly increased bradykinin-induced relaxation in the aorta of the
young rats and had no effects on respective relaxation in mesen-
teric arteries (Fig. 3). Ile-Pro-Pro caused at least as good relaxation
as Ang(1–7) pre-incubation and then subsequent bradykinin dos-
ing. We hypothesise, that Ile-Pro-Pro acts on bradykinin responses
in a similar mechanism as Ang(1–7).
Endothelial nitric oxide (NO) is the main player of endothelium-
dependent vasodilatation. In the present study, NOS inhibition
totally abolished relaxation in both vessels (Fig. 5). Interestingly,
COX enzyme inhibition, which blocks the production of endothe-
lial prostanoid formation, decreased relaxation in mesenteric artery
but tended to increase relaxation in aortas of the young rats. It might
be, that the balance between constricting and dilating prostanoids
differs from vessels to vessels in rats.
The pre-incubation with the bradykinin receptor antagonists
also only slightly decreased the ability of bradykinin to relax
the mesenteric arteries of young rats (Fig. 4). In the aorta,
bradykinin did not induce dilatation and receptor blockade had no
effects, conﬁrming earlier studies [28] that the bradykinin-induced
vasoconstriction affects prostanoid release. Bradykinin activates
phospholipase A2 (PLA2) which releases more arachidonic acid
from the cell membranes for prostanoid production [1,17,26]. This
phenome seems to be regulated through B2 but not B1 receptors.
Ang(1–7) induced only slight relaxation of the aortas of young
rats (Fig. 6), in support of the proposal that the aorta is not the best
vessel to undertake endothelium-based studies. The tripeptide Ile-
Pro-Pro had no effect on Ang(1–7)-induced relaxation, suggesting
that it does not directly affect mas-receptors or alternatively that
the receptors were already maximally stimulated by the speciﬁc
agonist Ang(1–7).
Interestingly, the mas-receptor antagonist, A-779, did not
totally inhibit Ang(1–7)-induced relaxation of the vessels of young
rats (Fig. 6). This can be explained by postulating that A-779 is only a
partial agonist of the mas-receptor at the concentration used (1 M
ﬁnal concentration). It is also possible that A-779 is degraded by
an unknown protease during pre-incubation (10 min) and forms
active fragments which then may act as receptor agonists. However,
these hypotheses will need to be evaluated in future studies. Other
tested mas-receptor antagonist, D-Pro7-Ang(1–7) abolished both
Ang(1–7)- and bradykinin-induced relaxation. D-Pro7-Ang(1–7) is
also an antagonist for the mas-related G-protein–coupled recep-
tor, member D (MrgD) [24] which is a receptor for alamandine, the
latest found compound of RAS. It has been shown that Ang(1–7)
is an agonist to MrgD receptors [13] and A-779 had no antagonist
effects on it [24]. It is possible that in our study Ang(1–7) caused
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asodilatation also through MrgD receptors which were blocked
sing D-Pro7-Ang(1–7).
In conclusion, we have demonstrated that bradykinin-induced
asorelaxation is age-dependent and that Ile-Pro-Pro, an ACE1-
nhibitor obtained from the dairy protein casein, is able to improve
radykinin’s properties in the vessels of aged rats. The mecha-
ism by which the tripeptide augments bradykinin vasodilatation
ay be similar to that encountered with Ang(1–7). Mas-receptor
ntagonist, D-Pro7-Ang(1–7) abolished bradykinin and Ang(1–7)
nduced relaxation totally. However, D-Pro7-Ang(1–7) is also an
ntagonist for MrgD receptors which may  partly regulate vasodi-
atation caused by these agents.
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